Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Anas Batikhi_2023
VIEWPOINTS

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Shots: Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCM He also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle management The interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…
June 2, 2023

Read more

VIEWPOINTS_Eric Halioua_2023
VIEWPOINTS

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

Shots: Eric shared the results from the first immunological results of its PDC-LUNG-101 P-I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate The interview shows PDC*line’s vision…
June 1, 2023

Read more

VIEWPOINTS_Monica Mann_2023
VIEWPOINTS

Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Shots: Monica spoke about the new data from its multiple sclerosis therapies portfolio presented at the 38th ECTRIMS meeting The highlights from the presentation were the safety and efficacy results of Vumerity, patient-reported outcomes from the treatment with Tysabri, and posters highlighting advances in digital health initiatives The interview shows how Biogen develops, and delivers…
May 31, 2023

Read more

VIEWPOINTS_Gregory Bell_2023
VIEWPOINTS

Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology

Shots: Gregory initially spoke about the Attralus licensing agreement with Ossianix’s brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease He also talked about how Ossianix VNAR antibody-based brain shuttle TXP1 will help Attralus to deliver AT-04, its developmental PAR therapeutic candidate,…
May 30, 2023

Read more

VIEWPOINTS_David Pendlebury_2023
VIEWPOINTS

David Pendlebury, Head of Research Analysis, Institute for Scientific Information Shares Insights from its Annual Highly Cited Researchers List

Shots: David first talked about Clarivate’s Highly Cited Researchers 2022 list. He said that the list picks out 6,938 individuals at universities, research institutes, and commercial organizations across 69 countries/regions He also elucidated the methodology used by Clarivate to create the list and how the pharma companies can benefit from this list to strengthen their…
May 29, 2023

Read more

VIEWPOINTS_Dr. Samiah Al-Zaidy_2023
VIEWPOINTS

Dr. Samiah Al-Zaidy, VP of Clinical Development at Passage Bio Shares Insights on Additional Interim Data from the Imagine-1 Study for GM1 Gangliosidosis

Shots: Samiah Al-Zaidy spoke about the interim clinical data from Imagine-1, P-I/II trial of PBGM01 for GM1 gangliosidosis presented at the 19th Annual WORLDSymposium 2023 She also talked about how the presentation at WORLDSymposium contributed to raising awareness about GM1 Gangliosidosis which is a rare and fatal disease The interview showcases Passage Bio’s mission to…
May 22, 2023

Read more

VIEWPOINTS_Dr. Harmony Garges_2023
VIEWPOINTS

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Shots: Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. Biktarvy She also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimen The interview gives an…
May 18, 2023

Read more

Load more